273 related articles for article (PubMed ID: 22160464)
21. Comparison of GnRH agonist versus luteal estradiol GnRH antagonist protocol using transdermal testosterone in poor responders.
Fàbregues F; Solernou R; Ferreri J; Guimerá M; Peralta S; Casals G; Peñarrubia J; Creus M; Manau D
JBRA Assist Reprod; 2019 Apr; 23(2):130-136. PubMed ID: 30614665
[TBL] [Abstract][Full Text] [Related]
22. A gonadotropin releasing hormone agonist trigger of ovulation with aggressive luteal phase support for patients at risk of ovarian hyperstimulation syndrome undergoing controlled ovarian hyperstimulation.
Liang IT; Huang HY; Wu HM; Wang HS; Yu HT; Huang SY; Chang CL; Soong YK
Taiwan J Obstet Gynecol; 2015 Oct; 54(5):583-7. PubMed ID: 26522115
[TBL] [Abstract][Full Text] [Related]
23. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment.
Beckers NG; Macklon NS; Eijkemans MJ; Ludwig M; Felberbaum RE; Diedrich K; Bustion S; Loumaye E; Fauser BC
J Clin Endocrinol Metab; 2003 Sep; 88(9):4186-92. PubMed ID: 12970285
[TBL] [Abstract][Full Text] [Related]
24. Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI.
Mohsen IA; El Din RE
Gynecol Endocrinol; 2013 Feb; 29(2):105-8. PubMed ID: 23134528
[TBL] [Abstract][Full Text] [Related]
25. Stop GnRH-Agonist Combined With Multiple-Dose GnRH-Antagonist Protocol for Patients With "Genuine" Poor Response Undergoing Controlled Ovarian Hyperstimulation for IVF.
Orvieto R; Kirshenbaum M; Galiano V; Elkan-Miller T; Zilberberg E; Haas J; Nahum R
Front Endocrinol (Lausanne); 2020; 11():182. PubMed ID: 32528403
[No Abstract] [Full Text] [Related]
26. Stimulation of the young poor responder: comparison of the luteal estradiol/gonadotropin-releasing hormone antagonist priming protocol versus oral contraceptive microdose leuprolide.
Shastri SM; Barbieri E; Kligman I; Schoyer KD; Davis OK; Rosenwaks Z
Fertil Steril; 2011 Feb; 95(2):592-5. PubMed ID: 21074154
[TBL] [Abstract][Full Text] [Related]
27. A randomized trial of microdose leuprolide acetate protocol versus luteal phase ganirelix protocol in predicted poor responders.
DiLuigi AJ; Engmann L; Schmidt DW; Benadiva CA; Nulsen JC
Fertil Steril; 2011 Jun; 95(8):2531-3. PubMed ID: 21324455
[TBL] [Abstract][Full Text] [Related]
28. Repeated application of luteal phase oestradiol/GnRH antagonist priming increases IVF success for poor ovarian reserve patients.
Ceyhan T; Ozturk M; Yıldız UG; Fidan U; Agacayak E; Ulubay M; Korkmaz C
J Obstet Gynaecol; 2023 Dec; 43(2):2211664. PubMed ID: 37289635
[TBL] [Abstract][Full Text] [Related]
29. A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders.
Cakmak H; Tran ND; Zamah AM; Cedars MI; Rosen MP
Fertil Steril; 2014 May; 101(5):1308-14. PubMed ID: 24636401
[TBL] [Abstract][Full Text] [Related]
30. [Gonadotropin-releasing hormone antagonist protocol in patients with risk of poor response to ovarian stimulation in IVF-ET].
Sun Y; Zhu YM
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2009 May; 38(3):305-10. PubMed ID: 19504641
[TBL] [Abstract][Full Text] [Related]
31. Which luteal phase support is better for each IVF stimulation protocol to achieve the highest pregnancy rate? A superiority randomized clinical trial.
Gizzo S; Andrisani A; Esposito F; Noventa M; Di Gangi S; Angioni S; Litta P; Gangemi M; Nardelli GB
Gynecol Endocrinol; 2014; 30(12):902-8. PubMed ID: 25268567
[TBL] [Abstract][Full Text] [Related]
32. [Cumulative live birth rates per oocytes retrieved cycle: evaluation of clinical outcomes of IVF/ICSI].
Wu CX; Zhang T; Shu L; Huang J; Diao FY; Ding W; Gao Y; Wang W; Mao YD; Cui YG; Liu JY
Zhonghua Fu Chan Ke Za Zhi; 2018 Mar; 53(3):160-166. PubMed ID: 29609229
[No Abstract] [Full Text] [Related]
33. The effect of luteal phase vaginal estradiol supplementation on the success of in vitro fertilization treatment: a prospective randomized study.
Engmann L; DiLuigi A; Schmidt D; Benadiva C; Maier D; Nulsen J
Fertil Steril; 2008 Mar; 89(3):554-61. PubMed ID: 17678651
[TBL] [Abstract][Full Text] [Related]
34. Cycle day, estrogen level, and lead follicle size: analysis of 27,790 in vitro fertilization cycles to determine optimal start criteria for gonadotropin-releasing hormone antagonist.
Lyttle Schumacher BM; Mersereau JE; Steiner AZ
Fertil Steril; 2018 Apr; 109(4):633-637. PubMed ID: 29605403
[TBL] [Abstract][Full Text] [Related]
35. Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders.
Chang X; Wu J
Gynecol Endocrinol; 2013 Mar; 29(3):196-200. PubMed ID: 23194136
[TBL] [Abstract][Full Text] [Related]
36. Growth Hormone Supplementation in the Luteal Phase Before Microdose GnRH Agonist Flare Protocol for In Vitro Fertilization.
Dunne C; Seethram K; Roberts J
J Obstet Gynaecol Can; 2015 Sep; 37(9):810-815. PubMed ID: 26605451
[TBL] [Abstract][Full Text] [Related]
37. Combined use of oestradiol and progesterone to support luteal phase in antagonist intracytoplasmic sperm injection cycles of normoresponder women: a case-control study.
Çakar E; Tasan HA; Kumru P; Cogendez E; Usal NT; Kutlu HT; Özkaya E; Eser SK
J Obstet Gynaecol; 2020 Feb; 40(2):264-269. PubMed ID: 31455122
[TBL] [Abstract][Full Text] [Related]
38. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
[TBL] [Abstract][Full Text] [Related]
39. Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection.
Qin N; Chen Q; Hong Q; Cai R; Gao H; Wang Y; Sun L; Zhang S; Guo H; Fu Y; Ai A; Tian H; Lyu Q; Daya S; Kuang Y
Fertil Steril; 2016 Aug; 106(2):334-341.e1. PubMed ID: 27114329
[TBL] [Abstract][Full Text] [Related]
40. Basal serum progesterone and history of elevated progesterone on the day of hCG administration are significant predictors of late follicular progesterone elevation in GnRH antagonist IVF cycles.
Venetis CA; Kolibianakis EM; Bosdou JK; Lainas GT; Sfontouris IA; Tarlatzis BC; Lainas TG
Hum Reprod; 2016 Aug; 31(8):1859-65. PubMed ID: 27301360
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
